 |
|
Early exposure to synthetic estrogen puts 'DES Daughters' at higher risk for breast cancer
August 07, 2006Philadelphia - So-called "DES daughters," born to mothers who used the anti-miscarriage drug diethylstilbestrol during pregnancy, are at a substantially greater risk of developing breast cancer compared to women who were not exposed to the drug in utero.
Reporting in the August issue of the journal Cancer Epidemiology, Biomarkers & Prevention, a nationwide team of researchers found that DES daughters over age 40 had 1.9 times the risk of developing breast cancer, compared to unexposed women of the same age. They also found that the relative risk of developing the cancer was even greater in DES daughters over age 50, but say the number of older women in their study group is, as yet, too small for a firm statistical comparison.
"This is really unwelcome news because so many women worldwide were prenatally exposed to DES, and these women are just now approaching the age at which breast cancer becomes more common," said the study's lead author, Julie Palmer, Sc.D., professor of epidemiology at the Boston University School of Public Health.
She said an estimated one to two million women in the U.S. were exposed to DES, which was frequently prescribed to women from the 1940s through 1960s to prevent miscarriages.
The ongoing study suggests that DES-exposed women are developing the typical range of breast cancers after age 40 at a faster rate than non-exposed women of the same ages. The researchers also found that the highest relative risk of developing breast cancer was observed in study participants from the cohorts with the highest cumulative doses of DES exposure.
Because of the increased risk observed for DES daughters, the authors urge women who know they were exposed to DES to have regular screening mammograms, and to think twice about using supplemental female hormones.
"DES daughters often ask us about use of these hormones," Palmer said. "It might be wise for exposed women to avoid such supplements. Use of hormone supplements is, in itself, an independent breast cancer risk factor, and women may choose not to compound their already increased risk."
When DES, a synthetic estrogen, was developed in 1938, physicians believed that low levels of estrogen in pregnant women led to spontaneous abortions or premature deliveries. In 1953, a clinical trial indicated no benefit with regard to miscarriage prevention. However, use continued in the U.S. until 1971 when researchers determined that DES greatly increased the risk of developing rare cancers of the vagina and cervix in DES daughters; the federal Food and Drug Administration subsequently banned use of the drug in pregnant women.
Later research demonstrated that DES increased the risk of breast cancer development in the mothers who used it.
To see if DES daughters and sons were also at greater risk of cancer or other serious illnesses, in 1992 the National Cancer Institute (NCI) funded a long-term study that assembled all known "cohorts," or groups of DES daughters that were already being studied (some since the 1970s), as well as a collection of unexposed women. This particular analysis included 4,817 exposed and 2,073 unexposed daughters, and, to date, 102 cases of invasive breast cancer have occurred in the combined group.
Factoring out other breast cancer risk variables such as the age when these women first gave birth, or their number of children, did not change DES daughters' relative risk of developing breast cancer, Palmer said. She adds that the breast cancer cases "tracked the normal range" of breast cancer subtypes, so are expected to be neither more nor less lethal than is commonly seen.
Only a few deaths have occurred in the combined group due to breast cancer, so survival statistics are not yet available, she said.
Scientifically, the study may be the first to provide direct evidence that prenatal exposure to excess estrogen may be a risk factor for development of breast cancer, Palmer said. "That theory has been around, but it has been difficult to study. The DES tragedy offers us a direct way to test the hypothesis," she said.
Although researchers do not know how DES may increase breast cancer risk, Palmer said some scientists believe the excess estrogen increases the number of breast tissue stem cells available at birth - cells which could malignantly transform into cancer.
If true that excess estrogen in utero impacts breast cancer risk later in life, "there is a concern that other environmental factors that increases fetal exposure to estrogenic compounds may do the same thing," Palmer said. "This study suggests that such environmental exposures may deserve more serious consideration."
American Association for Cancer Research
She said an estimated one to two million women in the U.S. were exposed to DES, which was frequently prescribed to women from the 1940s through 1960s to prevent miscarriages.
The ongoing study suggests that DES-exposed women are developing the typical range of breast cancers after age 40 at a faster rate than non-exposed women of the same ages. The researchers also found that the highest relative risk of developing breast cancer was observed in study participants from the cohorts with the highest cumulative doses of DES exposure.
Because of the increased risk observed for DES daughters, the authors urge women who know they were exposed to DES to have regular screening mammograms, and to think twice about using supplemental female hormones.
"DES daughters often ask us about use of these hormones," Palmer said. "It might be wise for exposed women to avoid such supplements. Use of hormone supplements is, in itself, an independent breast cancer risk factor, and women may choose not to compound their already increased risk."
When DES, a synthetic estrogen, was developed in 1938, physicians believed that low levels of estrogen in pregnant women led to spontaneous abortions or premature deliveries. In 1953, a clinical trial indicated no benefit with regard to miscarriage prevention. However, use continued in the U.S. until 1971 when researchers determined that DES greatly increased the risk of developing rare cancers of the vagina and cervix in DES daughters; the federal Food and Drug Administration subsequently banned use of the drug in pregnant women.
Later research demonstrated that DES increased the risk of breast cancer development in the mothers who used it.
To see if DES daughters and sons were also at greater risk of cancer or other serious illnesses, in 1992 the National Cancer Institute (NCI) funded a long-term study that assembled all known "cohorts," or groups of DES daughters that were already being studied (some since the 1970s), as well as a collection of unexposed women. This particular analysis included 4,817 exposed and 2,073 unexposed daughters, and, to date, 102 cases of invasive breast cancer have occurred in the combined group.
Factoring out other breast cancer risk variables such as the age when these women first gave birth, or their number of children, did not change DES daughters' relative risk of developing breast cancer, Palmer said. She adds that the breast cancer cases "tracked the normal range" of breast cancer subtypes, so are expected to be neither more nor less lethal than is commonly seen.
Only a few deaths have occurred in the combined group due to breast cancer, so survival statistics are not yet available, she said.
Scientifically, the study may be the first to provide direct evidence that prenatal exposure to excess estrogen may be a risk factor for development of breast cancer, Palmer said. "That theory has been around, but it has been difficult to study. The DES tragedy offers us a direct way to test the hypothesis," she said.
Although researchers do not know how DES may increase breast cancer risk, Palmer said some scientists believe the excess estrogen increases the number of breast tissue stem cells available at birth - cells which could malignantly transform into cancer.
If true that excess estrogen in utero impacts breast cancer risk later in life, "there is a concern that other environmental factors that increases fetal exposure to estrogenic compounds may do the same thing," Palmer said. "This study suggests that such environmental exposures may deserve more serious consideration."
American Association for Cancer Research
Cancer Researchers at the University of Pennsylvania Discover What Makes Lymphomas Tick
University of Pennsylvania researchers and their colleagues at the Wistar Institute and University of Oxford have discovered the molecular process by which the PAX5 protein, necessary for lymphocyte development, promotes the growth of common lymphomas, thereby unveiling a potential new target in the fight against cancer.
Negative effects of plastic's additive blocked by nutrient supplements
Experiments in animals have provided additional and tantalizing evidence that what a pregnant mother eats can make her offspring more susceptible to disease later in life.
Carnegie Mellon, USDA report that Fe-TAML® catalysts degrade estrogenic compounds
Scientists from Carnegie Mellon University and the U.S. Department of Agriculture (USDA) have found that a rapid, environmentally friendly catalytic process involving Fe-TAML® activators and hydrogen peroxide breaks down two types of estrogenic compounds.
Common pesticide may reduce fertility in women
Methoxychlor (MXC), a common insect pesticide used on food crops, may interfere with proper development and function of the reproductive tract, leading to reduced fertility in women, researchers at Yale School of Medicine write in the August issue of Endocrinology.
More Synthetic Estrogen News Articles
| Natural and Synthetic Estrogens by Elke Dopp, Helga Stopper, Gerrit M. Alink | |
 | The 2006-2011 World Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals WHAT IS LATENT DEMAND AND THE P.I.E.?The concept of latent demand is rather subtle. The term latent typically refers to something that is dormant, not observable, or not yet realized. Demand is the notion of an economic quantity that a target population or market requires under different assumptions of price, quality, and distribution, among other factors. Latent demand, therefore, is commonly... |
| Synthetic approaches to miroestrol (Massachusetts Institute of Technology. Dept. of Chemistry. Thesis. 1975. Ph. D) by David Karl Minster | |
 | The 2007-2012 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in India by Philip M. Parker This study covers the latent demand outlook for estrogen hormones and synthetic substitute pharmaceuticals across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 5,000 cities in India. For each city in question, the percent share the city is of it’s state or union territory and... |
 | Induction of hypospadias in a murine model by maternal exposure to synthetic estrogens [An article from: Environmental Research] by K. Suk Kim, C.R. Torres, S. Yucel, K. Raimondo, Cu This digital document is a journal article from Environmental Research, published by Elsevier in 2004. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: We tested the hypothesis that maternal exposure to synthetic estrogen can cause hypospadias in male offspring and defined the... |
 | The 2007-2012 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in Greater China by Philip M. Parker This study covers the latent demand outlook for estrogen hormones and synthetic substitute pharmaceuticals across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as... |
| To Do No Harm:DES and the Dilemmas of Modern Medicine (DES is a synthetic estrogen hormone) by Roberta J. & Fisher, Susan M. (M.D.s) Apfel | |
 | Environmental signals: Synthetic humic substances act as xeno-estrogen and affect the thyroid system of Xenopus laevis [An article from: Chemosphere] by I. Lutz, Z. Jie, R. Opitz, W. Kloas, X. Ying, Menz This digital document is a journal article from Chemosphere, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: According to outdated paradigms humic substances (HS) are considered to be refractory or inert that do not directly interact with aquatic... |
 | The 2007-2012 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in Japan by Philip M. Parker This study covers the latent demand outlook for estrogen hormones and synthetic substitute pharmaceuticals across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,000 cities in Japan. For each city in question, the percent share the city is of it’s prefecture and of Japan is reported. These... |
 | The 2007-2012 Outlook for Estrogen Hormones and Synthetic Substitute Pharmaceuticals in the United States by Philip M. Parker This study covers the latent demand outlook for estrogen hormones and synthetic substitute pharmaceuticals across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given some 12,919 cities across in the United States. For each city in question, the percent share the city is of it’s state and of the United... |
| © 2008 BrightSurf.com |